|
Abraham Abuchowski, Ph.D. is a founder of Prolong Pharmaceuticals and will serve as the Company's President , COO and member of the Board of Directors. Dr. Abuchowski was the founder and past Chairman and CEO of Enzon, Inc., a multi-billion dollar, biopharmaceutical company that specialized in PEGylation technology. During his 13 years at Enzon (1983-1996), Dr. Abuchowski successfully commercialized PEGylation by gaining FDA approval for three protein-based drugs. Dr. Abuchowski was instrumental in helping Enzon mature from a developmental stage company to a fully integrated publicly traded biopharmaceutical company. Dr. Abuchowski holds a B.S. and Ph.D. in Biochemistry from Rutgers University. He is an internationally recognized authority on drug delivery and has published numerous scientific papers and several book chapters on therapeutic products. In 1994, Dr Abuchowski founded and served as the first Chairman of the Biotechnology Council of New Jersey. Dr. Abuchowski is one of New Jersey's top entrepreneurs and is recognized at both the state and national levels as an outstanding bioscience executive. | 